Abstract. Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality in China and the third leading cause of cancer mortality worldwide. The mechanisms involved in the development and progression of HCC are not well understood. In the present study, the functions of endothelin-1 (ET-1) in HCC were studied and its underlying mechanisms were investigated. ET-1, B-cell lymphoma 2 (Bcl-2), Bcl-2 related protein 4 (Bax), matrix metalloproteinase (MMP)-2 and MMP-9 expression was measured by reverse transcription-quantitative polymerase chain reaction and western blotting. Cell proliferation was measured via Cell Counting kit-8 assay. Flow cytometry was performed for cell cycle and apoptosis analysis. Migration was measured via Transwell assay. The results demonstrated that ET-1 expression significantly increased in HCC tissues compared with the normal tissues of patients in The Cancer Genome Atlas dataset (P<0.01). Furthermore, downregulation of ET-1 was able to significantly inhibit cell proliferation and growth in vitro (P<0.01) and in vivo (P<0.01), and induce cell cycle arrest (P<0.05) and apoptosis (P<0.01) in the HCC SMMC-7721 cell line. Bioinformatics analysis demonstrated that the cell apoptosis signaling pathway was activated by ET-1. The ratio of B-cell lymphoma (Bcl-2)-related protein 4 (Bax)/Bcl-2 was significantly increased by downregulation of ET-1 (P<0.01). ET-1 downregulation also inhibited migration of SMMC-7721 cells (P<0.05) via decreasing levels of matrix metalloproteinase (MMP)-2 (P<0.05) and MMP-9 (P>0.05). These results suggest that ET-1 may be able to affect the apoptosis and migration of HCC cells via modulation of the Bax/Bcl-2 ratio and expression levels of MMP-2 and MMP-9, which indicates that ET-1 maybe a potential novel target for HCC treatment.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the third leading cause of cancer mortality worldwide, and, in Asia and Africa, is the most prevalent type of liver cancer with a poor prognosis (1,2). Hepatocarcinogenesis is associated with the gradual progression from hepatitis to fibrosis and cirrhosis, and ultimately hepatocellular carcinoma (3). HCC development and progression in humans is a long-term, multi-step process, which is characterized by the accumulation of genetic and epigenetic alterations (4), which is associated with sequential evolution of morphologically distinct stages culminating in the formation of fully developed HCC (5). Therapeutic treatments for advanced and metastatic HCC are limited, in part due to the fact that the underlying molecular mechanisms of development and progression are unclear (6,7).

Endothelin 1 (ET-1) is a vasoconstrictor protein that has been implicated in lethal metastasis (8). To date, the majority of studies into the underlying mechanisms of HCC progression have focused on ET-1 due to its strong biological activity (9,10). ET-1 has previously been demonstrated to serve an important role in the development and progression of various human cancers including ovarian, bladder and prostate cancer (8,11,12), which suggests that it may promote cell proliferation, invasion and migration, thus enhancing tumor growth and angiogenesis. ET-1 secretion in HCC is stimulated by various cytokines and growth factors (13). Elevated levels of ET-1 have been observed in HCC tissues compared with corresponding normal liver tissues (14). It has previously been demonstrated that ET-1 upregulation increases HCC cell proliferation, invasion and migration, and inhibits apoptosis (15). Furthermore, microRNA-1 is able to inhibit HCC cell proliferation partially by targeting ET-1 (16). These findings suggest that ET-1 may contribute to the development of HCC.
In the present study, the functions of ET-1 in HCC proliferation, apoptosis and migration were investigated. It was observed that ET-1 was increased in HCC cell lines compared with the normal hepatocellular L02 cells. Silencing of ET-1 via short hairpin (sh) RNA transfection inhibited the proliferation of HCC SMMC-7721 cells and tumor growth in vitro and in vivo. In addition, downregulation of ET-1 led to apoptosis promotion and migration suppression via increasing the ratio of B-cell lymphoma (Bcl-2) -related protein 4 (Bax)/Bcl-2 and decreasing the expression of matrix metalloproteinase (MMP)-2 and MMP-9. These findings supported the role of ET-1 in the development and progression of HCC and suggested that ET-1 may act as an effective target for HCC treatment.

Materials and methods

Bioinformatics analysis. Data from 100 HCC and 35 normal tissues were downloaded from The Cancer Genome Atlas (TCGA, cancergenome.nih.gov) and analyzed via gene set enrichment analysis (GSEA). GSEA was performed using the GSEA software, version 2.0.1, obtained from the Broad Institute (www.broad.mit.edu/gsea) as previously described (17,18). Ethical approval for the present study was provided by the Independent Ethics Committee of Hubei University of Chinese Medicine, Ministry of Education Key Laboratory of Traditional Chinese Medicine Resources and Compounds (Hubei, China).

Cell culture and lentivirus transfection. HCC cell lines (HepG2, Hep3B and SMMC-7721), and the human hepatic cell line (L02) were obtained from JRDun Biotechnology Co., Ltd. (Shanghai, China), cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. The SMMC-7721 cells were analyzed 48 h after transfection. Empty lentivirus vectors were used as a negative control (NC). The SMMC-7721 cells were analyzed by 48 h post-transfection.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from the HCC cell lines including HepG2, Hep3B and SMMC-7721 using TRIzol reagent at -80°C. cDNA was synthesized using an M-MLV RT reagent kit (Thermo Fisher Scientific, Inc.). DNase I treatment was used to remove genomic DNA. The reaction mixture contained RNA-Primer mix (12 µl), 5X RT Reaction buffer (5 µl), 25 mM dNTPs (1 µl), 25 U/µl RNase inhibitor (1 µl), 200 U/µl M-MLV RTase (1 µl), Oligo (d(T)18) (1 µl) and DNase-free ddH2O (4 µl). PCR amplification was performed using Maxima SYBR Green/ROX qPCR Master Mix (K0223; Finnzymes; Thermo Fisher Scientific, Inc.) on the ABI (ABI-7500) qPCR platform (Invitrogen; Thermo Fisher Scientific, Inc.). The reaction mixture contained SYBRGreen Mix (12.5 µl), forward primer (0.5 µl), reverse primer (0.5 µl), ddH2O (9.5 µl) and cDNA (2 µl). GAPDH RNA was used as an internal control to normalize the expression of ET-1. The PCR primers for ET-1 and GAPDH are: ET-1, forward: 5'-GCCCTGTCTGAGGCCATG-3'; reverse: 5'-GCTGAGGTTCCATT GTC-3'; and GAPDH, forward: 5'-CACCCACTCTCACC CTTTG-3', reverse: 5'-CCACACCCCTGTTTGTAAG-3'. The PCR cycling conditions were as follows: 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 45 sec, and a final extension step of 95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec and 60°C for 15 sec. Relative ET-expression levels were quantified using the 2^{-ΔΔCq} method (19). The experiment was repeated three times.

Western blot analysis. Isolated proteins were isolated using RIPA buffer containing 50 mM Tris-HCl, (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, phosphatase and protease inhibitor cocktail (Merck Millipore, Darmstadt, Germany) at 4°C for 20 min, followed by centrifugation at 12,000 x g for 1 min at 25°C. Equivalent quantities (50 µg) of protein lysates were separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes (Merck Millipore). Membranes were blocked in fat-free milk overnight at 4°C and subsequently incubated with primary antibodies: anti-ET-1 (cat. no. ab117757; Abcam, Cambridge, UK; 1:1,000) and anti-GAPDH (cat. no. ab9485; Abcam; 1:1,500) at 4°C overnight. Membranes were subsequently washed three times with TBS with Tween-20 (Amresco, LLC, Solon, OH, USA) for 5 min and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (cat. no. A0208; Beyotime Institute of Biotechnology; 1:1,000) at 37°C for 1 h. Signals were detected using an electrochemiluminescence system (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol and signal intensity was determined using ImageJ software version 1.46 (National Institutes of Health, Bethesda, MD, USA).

Cell proliferation assay. SMMC-7721 cells (3x10^3 cells/well) transfected with or without ET-1 shRNA were seeded in a 96-well plate and incubated at 37°C for 24, 48 and 72 h. Cell proliferation was assessed every 24 h throughout the experiment using a Cell Counting kit-8 (CCK-8; Dojindo Molecular Biosciences). The proliferation of transfected cells was determined using a flow cytometer (BD Accuri C6 version 1.0.264.21 software; BD Biosciences).
Cell migration assay. SMMC-7721 cells transfected with or without ET-1 shRNA were resuspended in 100 µl RPMI-1,640 medium and placed into the upper chamber of a Transwell support and incubated for 24 h at room temperature. Migratory cells were fixed with 4% polyoxymethylene (China National Pharmaceutical Group Corp., Beijing, China) and stained with 0.2% crystal violet. Evaluation of migrated cells was performed using a biological fluorescence microscope (CX41RF; Olympus Corporation, Tokyo, Japan).

In vivo assay. For the in vivo experiment, five-week-old male nude mice (n=12; 15-18 g) were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). A total of 1x10⁷ SMMC-7721 cells stably expressing shRNA or NC were injected into the right flanks of nude mice to induce tumorigenesis. Mice were housed in the animal facility at a temperature of 25°C and humidity of 60-70% and subjected to a 12-h light-dark cycle with ad libitum access to food and water. The size of tumors was determined at six weeks post-injection as previously described (20). At 42 days post-injection, mice were sacrificed via anesthesia with 3% sodium pentobarbital (40 mg/kg; Sigma-Aldrich; Merck Millipore) via intraperitoneal injection and cervical dislocation was performed. Ethical approval was provided by the Independent Ethics Committee of Hubei University of Chinese Medicine, Ministry of Education Key Laboratory of Traditional Chinese Medicine Resources and Compounds.

Statistical analysis. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Comparisons among groups were made using two-tailed Student's t-tests. P<0.05 was considered to indicate a statistically significant difference.

Results

ET-1 is upregulated in HCC tissues and cell lines. To identify the functions of ET-1 in HCC, ET-1 expression was assessed using bioinformatics analysis and RT-qPCR. The results demonstrated that ET-1 expression was significantly increased in the tissues of patients with HCC compared with normal hepatic tissues in the TCGA dataset (P<0.001; Fig. 1A). The expression of ET-1 in HCC cell lines including L02, HepG2, Hep3B and SMMC-7721 were also examined, with a significant upregulation of ET-1 observed in all HCC cells compared with the normal hepatic L02 cells, most notably in the SMMC-7721 cell line (P<0.01 for HepG2 cells; P<0.001 for Hep3B and SMMC-7721 cells; Fig. 1B). As a result, SMMC-7721 cells were used for all subsequent experiments. These results suggest that ET-1 may function as a tumor promoter in HCC.

Effect of ET-1 on cell proliferation in vitro and in vivo. To investigate the roles of ET-1 in HCC development and progression, ET-1 shRNA and NC shRNA were transfected into SMMC-7721 cells. ET-1 mRNA expression was significantly reduced by 47.5% in SMMC-7721 cells transfected with ET-1 shRNA compared with the NC group (P<0.01; Fig. 2A). ET-1 protein level was markedly decreased in the ET-1 shRNA group compared with the NC and control groups (Fig. 2B).

The carcinogenesis of ET-1 in SMMC-7721 cells was investigated. CCK-8 was used to measure the proliferation of SMMC-7721 cells transfected with ET-1 shRNA in vitro. It was demonstrated that downregulation of ET-1 significantly inhibited the proliferation of SMMC-7721 cells compared with the NC group (P<0.05 for 48 h and P<0.01 for 72 h; Fig. 2C). The effect of ET-1 on tumor growth in vivo was subsequently examined. As illustrated in Fig. 2D, the tumor grew markedly faster in mice injected with SMMC-7721 cells transfected with ET-1 shRNA compared with those transfected with NC shRNA. These data indicate that ET-1 downregulation is able to suppress tumor growth both in vitro and in vivo.

Effect of ET-1 on cell cycle and apoptosis of SMMC-7721. At 48 h post-transfection, flow cytometry was performed to analyze the cell cycle and apoptosis of SMMC-7721 cells. Cell cycle analysis revealed that ET-1 downregulation significantly increased the percentage of cells in G1 phase (P<0.001) and significantly decreased the percentage of cells in S phase (P<0.001), suggesting that downregulation of ET-1 resulted in cell cycle arrest in G1 phase (Fig. 3A and B). The effect of ET-1 on cell apoptosis was assessed and the results of an Annexin V-APC/PI staining assay revealed that ET-1 downregulation also significantly induced cell apoptosis of SMMC-7721 cells by 6.73-fold compared with the NC group (P<0.001; Fig. 3C and D).

Cell apoptosis pathway predicated to be regulated by ET-1. To further characterize the function of ET-1 in HCC, a GSEA was performed. mRNA profiling microarray data of HCC tissues were retrieved from TCGA dataset. Based on the median expression level (0.018) of ET-1, HCC tissues were divided into ET-1 high (>0.018) and ET-1 low groups (<0.018). A ranked gene list was generated by comparing the mRNA microarray data of the ET-1 high group with the ET-1 low group (ET-1 high vs. low). The inverse correlation between the expression levels of ET-1 and multiple genes in the cell apoptosis pathway indicated that ET-1 may positively regulate this pathway (Fig. 4A).

The expression of cell apoptosis-associated genes was evaluated at mRNA and protein levels in SMMC-7721 cells. The results demonstrated that the ratio of Bax/Bcl-2 was significantly increased in SMMC-7721 cells transfected with ET-1 shRNA at mRNA and protein levels, compared with the NC group (P<0.001; Fig. 4B and C).

Effect of ET-1 on cell migration of SMMC-7721. To investigate the effect of ET-1 on migration of SMMC-7721 cells, a Transwell assay was performed to evaluate migratory ability. ET-1 downregulation significantly inhibited the migration of SMMC-7721 cells in the ET-1 shRNA group compared with the NC group (P<0.001; Fig. 5A and B). The expression levels of MMP-2 and MMP-9 in SMMC-7721 cells were also evaluated and the mRNA levels of MMP-2 and MMP-9 were significantly inhibited in the ET-1 shRNA group compared with the NC group (P<0.001 for MMP-2, P<0.001 for MMP-9; Fig. 5C). Similarly, the protein levels of MMP-2 and MMP-9 were markedly inhibited by ET-1 downregulation compared with the NC group (Fig. 5D).
Discussion

HCC development is a multistep process, the mechanism of which remains to be elucidated. In Asia, >80% of HCC cases are induced by infection with hepatitis B virus (HBV) or hepatitis C virus (21). Several previous studies have demonstrated that increased levels of ET-1 expression in patients with HCC is correlated with cancer development and progression (16,22). In the present study, it was demonstrated that the expression of ET-1 was upregulated in HCC cell lines including HepG2, Hep3B and SMMC-7221 compared with normal hepatic L02 cells. The proliferation of HCC cells was analyzed via CCK-8 assay \textit{in vitro} and via the establishment of HCC in the mouse xenograft model \textit{in vivo}. Proliferation data indicated a decrease in cell proliferation and tumor growth in the ET-1 silenced SMMC-7221 cells and the HCC mouse model. Additionally, flow cytometry was used to perform cell cycle and apoptosis assays and the results indicated that ET-1 downregulation induced cell cycle arrest at G1 phase and promoted apoptosis via increasing the Bax/Bcl-2 ratio in SMMC-7221 cells. Notably, downregulation of ET-1 was demonstrated to significantly inhibit the migration of SMMC-7221 cells via downregulating the expression of MMP-2 and MMP-9, which is associated with HCC progression (23).

Additionally, flow cytometry was used to perform cell cycle and apoptosis assays and the results indicated that ET-1 downregulation induced cell cycle arrest at G1 phase and promoted apoptosis via increasing the Bax/Bcl-2 ratio in SMMC-7221 cells. Notably, downregulation of ET-1 was demonstrated to significantly inhibit the migration of SMMC-7221 cells via downregulating the expression of MMP-2 and MMP-9, which is associated with HCC progression (23).

Figure 1. ET-1 is upregulated in HCC tissues and cell lines. (A) Bioinformatics analysis demonstrated that ET-1 was upregulated in HCC tissues from the TCGA dataset compared with corresponding normal tissues. \(^{**}P<0.001\) vs. normal tissue. (B) Expression levels of ET-1 in human hepatocellular L02 cell line and three HCC cell lines measured using reverse transcription-quantitative polymerase chain reaction. \(^{**}P<0.01\) vs. L02 cell line, \(^{***}P<0.001\) vs. L02 cell line. ET, endothelin; HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas.

Figure 2. Downregulation of ET-1 inhibits HCC proliferation \textit{in vitro} and \textit{in vivo}. (A) Reverse transcription-quantitative polymerase chain reaction and (B) western blot analysis identified a reduction in ET-1 expression in SMMC-7721 cells treated with ET-1 shRNA. (C) Cell counting kit-8 assay identified a significant inhibition in proliferation of SMMC-7721 cells \textit{in vitro}. (D) Downregulation of ET-1 attenuated tumor growth in a mouse xenograft model (n=6). \(^{*}P<0.05\), \(^{**}P<0.01\) vs. NC shRNA group. ET, endothelin; HCC, hepatocellular carcinoma; sh, short hairpin; NC, negative control.
present study demonstrated that silencing ET-1 inhibited the proliferation of SMMC-7221 cells and tumor growth, which is concurrent with the findings of previous studies (22,26,27).

The cell cycle and apoptosis of SMMC-7221 cells transfected with ET-1 shRNA were examined to determine the mechanism by which ET-1 affects the development of HCC. The findings of the present study indicated that downregulation of ET-1 induced cell cycle arrest at G1 phase and induced apoptosis in SMMC-7221 cells. These findings are in accordance with those of previous studies which demonstrated that ET-1 promotes survival against cisplatin-induced apoptosis in osteosarcoma (28) and reduces apoptosis in human umbilical vein endothelial cells (29). The role of ET-1 in cell cycle and apoptosis may be achieved by ET-1-induced expression of apoptosis-related genes, such as Bax and Bcl-2. In the present study, downregulation of ET-1 induced a significant increase in the Bax/Bcl-2 ratio in mRNA and protein expression levels, suggesting that ET-1 is able to mediate cell apoptosis via changing the Bax/Bcl-2 ratio in SMMC-7221 cells. It has previously been reported that ET-1-induced upregulation of survivin may promote the resistance of myofibroblasts to apoptosis (30).

In the present study it was demonstrated that downregulation of ET-1 significantly inhibited migration of SMMC-7221 cells compared with the NC group, which is consistent with the findings of Lu et al (22). ET-1 is able to modulate migration in HCC cells and also many other types of cancer cells, such as melanoma (31), bovine corneal endothelial (32) and human chondrosarcoma cells (33). These findings indicate that ET-1 has a role in HCC migration that may be triggered by the ET-1-induced expression of migration-related genes. The expression levels of MMP-2 and MMP-9 in SMMC-7221 cells transfected with ET-1 shRNA were examined in the present study. The results demonstrated that downregulation of ET-1 significantly decreased the expression of MMP-2 and MMP-9 at mRNA and protein levels, suggesting that MMP-2 and MMP-9 may be associated with ET-1-mediated migration of SMMC-7221 cells. It has previously been reported that ET-1 promoted MMP-13 expression and migration in human chondrosarcoma cells via the focal adhesion kinase/phosphoinositide
Figure 4. KEGG apoptosis pathway is predicted to be regulated by ET-1. (A) Genes in the KEGG apoptosis pathway were significantly enriched in ET-1 higher expressed tumors vs. ET-1 lower expressed tumors. (B) Reverse transcription-quantitative polymerase chain reaction and (C) western blot analysis identified a significant increase in the ratio of Bax/Bcl-2 in SMMC-7721 cells. ***P<0.001 vs. NC shRNA group. KEGG, Kyoto Encyclopedia of Genes and Genomes; ET, endothelin; Bax, Bcl-2-like protein 4; Bcl, B-cell lymphoma; NC, negative control; sh, short hairpin.

Figure 5. Downregulation of ET-1 inhibits HCC migration. (A) The migration of SMMC-7721 cells was measured using a Transwell assay. (B) Downregulation of ET-1 significantly inhibited migration of SMMC-7721 cells. (C) Reverse transcription-quantitative polymerase chain reaction and (D) western blot analysis identified a significant decrease in the expression of MMP-2 and MMP-9 in SMMC-7721 cells. ***P<0.001 vs. NC shRNA group. ET, endothelin; HCC, hepatocellular carcinoma; MMP, matrix metalloproteinase; NC, negative control; sh, short hairpin.
3-kinase/protein kinase B/mechanistic target of rapamycin pathways (34) and enhanced astrocytic migration via activation of MMP-9 (35).

In conclusion, the results of the present study indicate that liver-specific expression of ET-1 induces hepatocarcinogenesis in SMMC-7221 cells. The downregulation of ET-1 in SMMC-7221 cells inhibited cell proliferation and migration, and induced cell cycle arrest and cell apoptosis. Many genes associated with apoptosis and migration were regulated in SMMC-7221 cells stably expressing ET-1 shRNA; the ratio of Bax/Bcl-2 was increased and expression levels of MMP-2 and MMP-9 decreased. The findings of the present study provide further insight into the regulatory mechanisms of ET-1 in HCC. Further investigation is required to address the functional effects of ET-1 in HCC tissues and cells, such as clinical characteristics and metastasis.

References